Details of the Drug
General Information of Drug (ID: DMCDYW7)
Drug Name |
Nicardipine
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Nicardipino; Nicardipinum; Cardene IV; Nicardipine LA; Cardene (TN); Nicardipine (INN); Nicardipine [INN:BAN]; Nicardipino [INN-Spanish]; Nicardipinum [INN-Latin]; Y-93; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
|
||||||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||||||
Therapeutic Class |
Antihypertensive Agents
|
||||||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||||||
Structure | |||||||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 479.5 | |||||||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.8 | ||||||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 10 | ||||||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 8 | ||||||||||||||||||||||||||
ADMET Property |
|
||||||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||||||
Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||||||||||
Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | ||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug Transporter (DTP) |
|
|||||||||||||||||||||||||||||||||||||||||
Drug-Metabolizing Enzyme (DME) |
|
|||||||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Same Disease as Nicardipine
Coadministration of a Drug Treating the Disease Different from Nicardipine (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2559). | ||||
---|---|---|---|---|---|
2 | Nicardipine FDA Label | ||||
3 | BDDCS applied to over 900 drugs | ||||
4 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
5 | Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose | ||||
6 | Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20. | ||||
7 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | ||||
8 | Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605. | ||||
9 | Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5. | ||||
10 | Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. | ||||
11 | Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167] | ||||
12 | Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI. | ||||
13 | Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107] | ||||
14 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
15 | Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984] | ||||
16 | Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086] | ||||
17 | Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL. | ||||
18 | Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA. | ||||
19 | Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ. | ||||
20 | Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028] | ||||
21 | Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA. | ||||
22 | Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
23 | Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA. | ||||
24 | Cerner Multum, Inc. "Australian Product Information.". | ||||
25 | Canadian Pharmacists Association. | ||||
26 | Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA. | ||||
27 | Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ. | ||||
28 | Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ. | ||||
29 | Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424] | ||||
30 | Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ. | ||||
31 | EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.". | ||||
32 | Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385] | ||||
33 | Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA. | ||||
34 | Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911] | ||||
35 | Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA. | ||||
36 | Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ. | ||||
37 | Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI. | ||||
38 | Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC. | ||||
39 | Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA. | ||||
40 | Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT. | ||||
41 | Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE. | ||||
42 | Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ. | ||||
43 | Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ. | ||||
44 | Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ. | ||||
45 | Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ. | ||||
46 | Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN. | ||||
47 | Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
48 | Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC. | ||||
49 | Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
50 | Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA. | ||||
51 | Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA. | ||||
52 | Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO. | ||||
53 | Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
54 | Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
55 | Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ. | ||||
56 | Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ. | ||||
57 | Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA. | ||||
58 | EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.". | ||||
59 | Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ. | ||||
60 | Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA. | ||||
61 | Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA. | ||||
62 | Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA. | ||||
63 | Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
64 | Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA. | ||||
65 | DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902] | ||||
66 | Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA. | ||||
67 | Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16. [PMID: 7519161] | ||||
68 | Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ. | ||||